The FDA accepted an sNDA and granted priority review for elinzanetant to treat VMS in women receiving endocrine therapy to treat or prevent HR+ breast cancer.
|Videos|February 23, 2022
- Vol 67 No 3
- Volume 67
- Issue 3
Myfembree for moderate-to-severe endometriosis pain: Potential for adolescents
Author(s)Lindsey Carr, Editor
Contemporary OB/GYN® Associate Editor Lindsey Carr sat down with Jessica Shim, MD, an attending at in the Division of Gynecology, Department of Surgery, Boston Children’s Hospital; Harvard Medical School Boston, Massachusetts, to discuss Myfembree (relugolix, estradiol, and norethindrone acetate tablets; Myovant Sciences, Pfizer) and its possible approval in May 2022.
Advertisement
If approved, relugolix, estradiol, and norethindrone acetate tablets (Myfembree; Myovant Sciences, Pfizer) could be game-changing for pain management in women with moderate-to-severe endometriosis pain.
Articles in this issue
over 4 years ago
Delayed diagnosis of a bowel injury at laparoscopyover 4 years ago
Understanding abnormal uterine bleeding in adolescentsover 4 years ago
Adnexal torsion requires careful diagnosis, managementover 4 years ago
Bringing awareness to endometriosisover 4 years ago
Celebrating Laura E. Riley, MDover 4 years ago
Prenatal genetic data sharing and privacy risksover 4 years ago
Patient perspectives on vulvovaginal candidiasisover 4 years ago
Provider bias in contraceptive counselingAdvertisement
Related to this article
Anita Nelson, MD, discusses the FDA's approval extending etonogestrel implant use to 5 years and the new REMS certification clinicians must complete by February 23, 2027.
Get caught up with Contemporary OB/GYN! This list helps you navigate our top stories from the week, all in one place.
The FDA office of Women's Health and Center for Drug Evaluation and Research and hosting a public workshop with a focus on testosterone use in menopausal women.
FDA accepted for review an sNDA for MIUDELLA copper IUD for a 6-year duration, with a PDUFA date in Q2 2027.
Get caught up with Contemporary OB/GYN! This list helps you navigate our top stories from the week, all in one place.
Atogepant reduced perimenstrual migraine days vs. placebo and met all 8 secondary endpoints in the Phase 3 LUNA study.
AJOG research shows a cytokine storm could be detectable in maternal blood before the clinical onset of AFE.
Advertisement
Advertisement
Trending on Contemporary OB/GYN
1
FDA grants priority review to elinzanetant for VMS in women receiving endocrine therapy for breast cancer
2
Q&A: Anita Nelson, MD, on etonogestrel implant's 5-year approval and REMS certification
3
Missed & Dismissed: The diagnostic gap starts in childhood
4
FAQ: How should clinicians manage histoplasmosis during pregnancy?
5